Roche Prepares Purchasing 89bio
(MENAFN) Swiss drugmaker Roche has reached an agreement to buy American biotech firm 89bio for $3.5 billion, aiming to broaden its portfolio in liver-related illnesses.
The company declared that 89bio, headquartered in San Francisco, accepted Roche’s proposal of $14.50 in cash for each share.
The arrangement is valued at nearly $2.4 billion, with investors also set to obtain a "non-tradeable contingent value right (CVR)" worth up to $6 for every share. This raises the overall acquisition figure to $3.5 billion.
According to a statement from Roche, "89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage). The transaction is expected to close in the fourth quarter of 2025."
The purchase highlights Roche’s commitment to progressing pioneering treatments in cardiovascular, renal, and metabolic disorders (CVRM), particularly for individuals facing obesity, excess weight, and associated medical problems such as MASH, the statement noted.
Pegozafermin presents a unique mode of action that may deliver improved effectiveness and tolerability, while also paving the way for potential combination strategies with incretins, fostering synergies with Roche’s broader CVRM research portfolio.
The company declared that 89bio, headquartered in San Francisco, accepted Roche’s proposal of $14.50 in cash for each share.
The arrangement is valued at nearly $2.4 billion, with investors also set to obtain a "non-tradeable contingent value right (CVR)" worth up to $6 for every share. This raises the overall acquisition figure to $3.5 billion.
According to a statement from Roche, "89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage). The transaction is expected to close in the fourth quarter of 2025."
The purchase highlights Roche’s commitment to progressing pioneering treatments in cardiovascular, renal, and metabolic disorders (CVRM), particularly for individuals facing obesity, excess weight, and associated medical problems such as MASH, the statement noted.
Pegozafermin presents a unique mode of action that may deliver improved effectiveness and tolerability, while also paving the way for potential combination strategies with incretins, fostering synergies with Roche’s broader CVRM research portfolio.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Japan Skin Care Products Market Size Worth USD 11.6 Billion By 2033 CAGR: 4.18%
- Permissionless Data Hub Baselight Taps Walrus To Activate Data Value Onchain
- Chaingpt Pad Unveils Buzz System: Turning Social Hype Into Token Allocation
- Newcastle United Announce Multi-Year Partnership With Bydfi
- PLPC-DBTM: Non-Cellular Oncology Immunotherapy With STIPNAM Traceability, Entering A Global Acquisition Window.
- Origin Summit Unveils Second Wave Of Global Icons Ahead Of Debut During KBW
Comments
No comment